A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merrimack Pharmaceuticals
• Collaborator: Sanofi
• Treatments: Antibodies, Monoclonal; Camptothecin; Cetuximab; Irinotecan

Criteria

Inclusion Criteria:

• No standard options remaining

• Adequate liver and kidney functions

• 18 years of age or above

Exclusion Criteria:

• History of any secondary active cancer in the last 3 years.

• Pregnant or breast feeding

• History of severe allergic reactions or contraindications to cetuximab or irinotecan